IntelGenx Technologies Corp. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-12-04: Form 8-K; Period of report 2023-12-02; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2023-11-28: Form 8-K; Period of report 2023-11-28; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.03.
- 2023-10-12: Form 8-K; Period of report 2023-10-06; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2023-08-31: Form 8-K; Period of report 2023-08-31; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-12-04 | 8-K | 2023-12-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 2, 2023, the board of directors (the "Board") of IntelGenx Technologies Corp. (the "Corporation") received the resignations of Frank Stegert and Srinivas Rao, who were the Board designees pursuant the purchaser rights agreement by and between the Corporation and ATAI Life Sciences AG ("atai"). | form8k.htm |
| 2023-11-28 | 8-K | 2023-11-28 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 IntelGenx Technologies Corp. (the "Company" or "IntelGenx") held a Special Meeting of Shareholders on November 28, 2023 (the "Special Meeting"). 5.07 The Special Meeting was held in a virtual-only format, for those who were shareholders of the Company at the close of business on October 2, 2023 (the "Record Date"), pursuant to notice and proxy materials duly communicated to them. | form8k.htm |
| 2023-10-12 | 8-K | 2023-10-06 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 As previously disclosed on the Current Report on Form 8-K filed on August 31, 2023 (the "August Current Report") of Intelgenx Technologies Corp. (the "Corporation"), in connection with an initial private placement and offering of units (the "Initial Offering"), on August 31, 2023 (the "Initial Closing Date") the Corporation entered into an amending agreement (the "Amending Agreement"), in respect of the amended and restated loan agreement dated as of September 14, 2021 between the Corporation, as borrower, and ATAI Life Sciences AG ("atai"), as lender with respect to a US$8.5 million loan (the "Loan"), pursuant to which, among other things, the Corporation and atai agreed, subject to obtaining approval of the Toronto Stock Exchange ("TSX"), (i) to enter into a second amended and restated loan agreement (the "Second Loan Agreement"), effective September 30, 2023, to provide, among other things, for the ability for atai to convert the principal (the "Principal") and accrued interest outstanding (the "Interest") under the Loan into up to 56,435,098 shares ("Shares") of common stock of the Corporation ("Common Stock") at a price of US$0.185 per Share (the "Conversion Feature"), and (ii) to enter into an amendment (the "atai Subscription Agreement Amendment") to that certain subscription agreement between the Corporation and atai dated August 31, 2023, to provide atai with the right (the "Call Option") to purchase up to 7,401 additional units (the "Call Option Units"), with each unit consisting of (a) one US$1,000 principal amount convertible promissory note (each, a "Note") and (b) 5,405 common stock purchase warrants (each, a "Warrant") at any time prior to August 31, 2026. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. 3.02 The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02 in its entirety. | form8k.htm |
| 2023-08-31 | 8-K | 2023-08-31 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On August 31, 2023 (the "Initial Closing Date"), IntelGenx Technologies Corp. (the "Corporation") closed the first tranche of its non-brokered private placement and offering (the "Offering") of (a) units to US subscribers at a price of US$1,000 per US Unit (the "US Units"), with each US Units consisting of (i) US$1,000 principal amount convertible promissory note (the "US Notes") and (ii) 5,405 common stock purchase warrants (the "US Warrants") to purchase common stock of the Corporation (the "Shares"), and (b) units to Canadian and other subscribers located outside the US (the "Cdn Units") at a price of C$1,000 per Cdn Unit, with each Cdn Unit consisting of (i) a C$1,000 principal amount convertible promissory note (the "Cdn Notes" and, together with the US Notes, the "Notes") and 4,000 common stock purchase warrants (the "Cdn Warrants" and, together with the US Warrants, the "Warrants"). 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K under the heading "Amendment to Amended and Restated Term Loan" is incorporated by reference into this Item 2.03. 3.02 The information set forth under Item 1.01 of this Current Report on Form 8-K under the headings "Offering" and "Call Option" are hereby incorporated by reference into this Item 3.02 in its entirety. | form8k.htm |
| 2023-07-21 | 8-K | 2023-07-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 J. Bernard Boudreau resigned from his position as Director of IntelGenx Technologies Corp. (the "Company"), effective July 21, 2023. | form8k.htm |
| 2023-05-10 | 8-K | 2023-05-09 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 IntelGenx Technologies Corp. (the "Company" or "IntelGenx") held its Annual Meeting of Shareholders on May 9, 2023 (the "Annual Meeting"), in a virtual-only format, for those who were shareholders of the Company at the close of business on March 13, 2023 (the "Record Date"), pursuant to notice and proxy materials duly communicated to them. | form8k.htm |
| 2023-04-18 | 8-K | 2023-04-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 IntelGenx Technologies Corp. (the "Company") announced that on April 13, 2023, Horst G. Zerbe resigned from his position as chief executive officer ("CEO") of the Company. | form8k.htm |
| 2023-03-27 | 8-K/A | 2023-03-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The Board of Directors of IntelGenx Technologies Corp. (the "Company") announced that on March 20, 2023, Dr. David Kideckel was appointed to serve as Senior Vice President, Head of Corporate Development & Strategic Alliances of IntelGenx Corp., the Company's operating subsidiary, pursuant to the terms and conditions of a Memorandum of Agreement (the "Agreement"). | form8ka.htm |
| 2023-03-24 | 8-K | 2023-03-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The Board of Directors of IntelGenx Technologies Corp. (the "Company") announced that on March 20, 2023, Dr. David Kideckel was appointed to serve as Senior Vice President, Head of Corporate Development & Strategic Alliances of IntelGenx Corp., the Company's operating subsidiary, pursuant to the terms and conditions of a Memorandum of Agreement (the "Agreement"). | form8k.htm |
| 2023-03-24 | 8-K | 2023-03-21 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On March 21, 2023 (the "Closing Date"), IntelGenx Technologies Corp. (the "Company") closed an offering by way of private placement in the United States (the "Private Placement") of unsecured convertible notes (the "Notes"). 2.03 The disclosure set forth in Item 1.01 to this Current Report on Form 8-K is incorporated into this item by reference. 3.02 The disclosure set forth in Item 1.01 to this Current Report on Form 8-K is incorporated into this item by reference. | form8k.htm |
| 2023-02-21 | 8-K | 2023-02-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Dana Matzen resigned from her position as Vice President, Business and Corporate Development of IntelGenx Corp., a wholly-owned subsidiary of IntelGenx Technologies Corp. (the "Company"), effective March 10, 2023. | form8k.htm |